Mitotic entry upon Topo II catalytic inhibition is controlled by Chk1 and Plk1

Area of Science:

• Cell cycle regulation
• DNA replication and repair
• Cancer biology

Background:

• The decatenation checkpoint, activated by topoisomerase II inhibition, delays mitosis during G2 phase.
• This checkpoint is less understood than the G2 DNA damage checkpoint and is often compromised in tumors.
• MCPH1 was recently identified as a key regulator of decatenation checkpoint adaptation.

Purpose of the Study:

• To elucidate the roles of checkpoint kinase 1 (Chk1) and polo-like kinase 1 (Plk1) in the decatenation checkpoint.
• To understand the molecular mechanisms underlying MCPH1-mediated adaptation to decatenation stress.
• To differentiate between checkpoint adaptation and recovery processes.

Main Methods:

• Investigated the functional requirements of Chk1 and Plk1 in response to topoisomerase II inhibition.
• Utilized cell lines with altered MCPH1 and Chk1 expression or function.
• Assessed G2 arrest, adaptation, and recovery phenotypes following checkpoint activation.

Main Results:

• Chk1 activity is essential for maintaining the G2 arrest induced by topoisomerase II inhibition.
• Loss of Chk1 function rescues decatenation checkpoint adaptation in MCPH1-deficient cells.
• Plk1 is required for bypassing the decatenation checkpoint arrest after Chk1 inhibition.
• MCPH1 counteracts Chk1-mediated Plk1 inactivation, facilitating checkpoint adaptation.
• MCPH1 function is not required for checkpoint recovery, suggesting distinct mechanisms.

Conclusions:

• MCPH1 plays a critical role in enabling decatenation checkpoint adaptation by modulating Chk1 and Plk1 activities.
• Checkpoint adaptation and recovery are distinct cellular processes regulated by different effectors.
• Understanding these pathways may offer insights into targeting cancer cell vulnerabilities.